Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Esophageal Cancer-Pipeline Review, H1 2015

Esophageal Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Esophageal Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Esophageal Cancer-Pipeline Review, H1 2015', provides an overview of the Esophageal Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Esophageal Cancer Overview 9

Therapeutics Development 10

Pipeline Products for Esophageal Cancer-Overview 10

Pipeline Products for Esophageal Cancer-Comparative Analysis 11

Esophageal Cancer-Therapeutics under Development by Companies 12

Esophageal Cancer-Therapeutics under Investigation by Universities/Institutes 17

Esophageal Cancer-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Esophageal Cancer-Products under Development by Companies 21

Esophageal Cancer-Products under Investigation by Universities/Institutes 25

Esophageal Cancer-Companies Involved in Therapeutics Development 26

Advantagene, Inc. 26

Advaxis, Inc. 27

Amgen Inc. 28

ArQule, Inc. 29

Aslan Pharmaceuticals Pte. Ltd. 30

AstraZeneca PLC 31

AVEO Pharmaceuticals, Inc. 32

Bellicum Pharmaceuticals, Inc. 33

Boehringer Ingelheim GmbH 34

Bristol-Myers Squibb Company 35

Celgene Corporation 36

Cellectar Biosciences, Inc. 37

Cerulean Pharma, Inc. 38

Daiichi Sankyo Company, Limited 39

Genmab A/S 40

GlaxoSmithKline plc 41

Glycotope GmbH 42

Hutchison MediPharma Limited 43

ImmunoFrontier, Inc. 44

ImmunoGen, Inc. 45

Immunomedics, Inc. 46

Karyopharm Therapeutics, Inc. 47

Mebiopharm Co., Ltd. 48

Meiji Seika Pharma Co., Ltd. 49

Merrimack Pharmaceuticals, Inc. 50

Novartis AG 51

Omeros Corporation 52

Omnitura Therapeutics Inc. 53

Oncolys BioPharma Inc. 54

Ono Pharmaceutical Co., Ltd. 55

Patrys Limited 56

Pfizer Inc. 57

Precision Biologics, Inc. 58

Proteo, Inc. 59

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 60

Supratek Pharma Inc. 61

Synta Pharmaceuticals Corp. 62

Takara Bio Inc. 63

Transgene Biotek Limited 64

Zhejiang BetaPharma Co., Ltd. 65

Esophageal Cancer-Therapeutics Assessment 66

Assessment by Monotherapy Products 66

Assessment by Target 67

Assessment by Mechanism of Action 70

Assessment by Route of Administration 73

Assessment by Molecule Type 75

Drug Profiles 77

1-BB1-Drug Profile 77

ADXS-HER2-Drug Profile 79

afatinib-Drug Profile 80

alpelisib-Drug Profile 84

AMG-337-Drug Profile 86

binimetinib-Drug Profile 87

BMS-833923-Drug Profile 91

BPX-601-Drug Profile 93

Cell Therapy 1 for Oncology-Drug Profile 94

Cell Therapy to Target NY-ESO-1 for Oncology-Drug Profile 95

cetuximab biobetter-Drug Profile 96

CRLX-101-Drug Profile 97

dacomitinib-Drug Profile 99

DKN-01-Drug Profile 101

doxorubicin-Drug Profile 103

Elafin-Drug Profile 105

ficlatuzumab-Drug Profile 108

ganetespib-Drug Profile 111

gefitinib-Drug Profile 115

Gene Therapy for Esophageal Cancer-Drug Profile 120

Gene Therapy to Activate p53 for Oncology-Drug Profile 121

GSK-2256098-Drug Profile 122

HMPL-309-Drug Profile 124

HMPL-813-Drug Profile 125

HuMax-TF-ADC-Drug Profile 126

I131-CLR1404-Drug Profile 127

icotinib hydrochloride-Drug Profile 129

IMF-001-Drug Profile 130

IMGN-289-Drug Profile 131

IMMU-132-Drug Profile 132

LJM-716-Drug Profile 133

MBP-426-Drug Profile 135

MM-111-Drug Profile 137

MMD-37K-Drug Profile 139

MVX-ONCO-1-Drug Profile 140

NEO-201-Drug Profile 141

nimotuzumab-Drug Profile 142

nivolumab (recombinant)-Drug Profile 145

OBP-301-Drug Profile 150

OMN-54-Drug Profile 152

paclitaxel albumin bound-Drug Profile 154

panitumumab-Drug Profile 158

PAT-LM1-Drug Profile 161

patritumab-Drug Profile 162

rAAV-VICN003-Drug Profile 164

rhLT28-171-Drug Profile 165

selinexor-Drug Profile 166

Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes-Drug Profile 170

Small Molecule to Target LGR5 for Esophageal Adenocarcinoma-Drug Profile 171

Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer-Drug Profile 172

talaporfin sodium-Drug Profile 173

TBI-1201-Drug Profile 176

TBL-0805E-Drug Profile 178

tivantinib-Drug Profile 179

Vaccine for Esophageal Cancer-Drug Profile 182

Vaccine for Oncology-Drug Profile 183

varlitinib-Drug Profile 184

Esophageal Cancer-Recent Pipeline Updates 186

Esophageal Cancer-Dormant Projects 253

Esophageal Cancer-Discontinued Products 256

Esophageal Cancer-Product Development Milestones 257

Featured News & Press Releases 257

Appendix 265

Methodology 265

Coverage 265

Secondary Research 265

Primary Research 265

Expert Panel Validation 265

Contact Us 265

Disclaimer 266

List of Tables

Number of Products under Development for Esophageal Cancer, H1 2015 14

Number of Products under Development for Esophageal Cancer-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 17

Number of Products under Development by Companies, H1 2015 (Contd..1) 18

Number of Products under Development by Companies, H1 2015 (Contd..2) 19

Number of Products under Development by Companies, H1 2015 (Contd..3) 20

Number of Products under Investigation by Universities/Institutes, H1 2015 21

Comparative Analysis by Late Stage Development, H1 2015 22

Comparative Analysis by Clinical Stage Development, H1 2015 23

Comparative Analysis by Early Stage Development, H1 2015 24

Products under Development by Companies, H1 2015 25

Products under Development by Companies, H1 2015 (Contd..1) 26

Products under Development by Companies, H1 2015 (Contd..2) 27

Products under Development by Companies, H1 2015 (Contd..3) 28

Products under Investigation by Universities/Institutes, H1 2015 29

Esophageal Cancer-Pipeline by Advantagene, Inc., H1 2015 30

Esophageal Cancer-Pipeline by Advaxis, Inc., H1 2015 31

Esophageal Cancer-Pipeline by Amgen Inc., H1 2015 32

Esophageal Cancer-Pipeline by ArQule, Inc., H1 2015 33

Esophageal Cancer-Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2015 34

Esophageal Cancer-Pipeline by AstraZeneca PLC, H1 2015 35

Esophageal Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 36

Esophageal Cancer-Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 37

Esophageal Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 38

Esophageal Cancer-Pipeline by Bristol-Myers Squibb Company, H1 2015 39

Esophageal Cancer-Pipeline by Celgene Corporation, H1 2015 40

Esophageal Cancer-Pipeline by Cellectar Biosciences, Inc., H1 2015 41

Esophageal Cancer-Pipeline by Cerulean Pharma, Inc., H1 2015 42

Esophageal Cancer-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 43

Esophageal Cancer-Pipeline by Genmab A/S, H1 2015 44

Esophageal Cancer-Pipeline by GlaxoSmithKline plc, H1 2015 45

Esophageal Cancer-Pipeline by Glycotope GmbH, H1 2015 46

Esophageal Cancer-Pipeline by Hutchison MediPharma Limited, H1 2015 47

Esophageal Cancer-Pipeline by ImmunoFrontier, Inc., H1 2015 48

Esophageal Cancer-Pipeline by ImmunoGen, Inc., H1 2015 49

Esophageal Cancer-Pipeline by Immunomedics, Inc., H1 2015 50

Esophageal Cancer-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 51

Esophageal Cancer-Pipeline by Mebiopharm Co., Ltd., H1 2015 52

Esophageal Cancer-Pipeline by Meiji Seika Pharma Co., Ltd., H1 2015 53

Esophageal Cancer-Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 54

Esophageal Cancer-Pipeline by Novartis AG, H1 2015 55

Esophageal Cancer-Pipeline by Omeros Corporation, H1 2015 56

Esophageal Cancer-Pipeline by Omnitura Therapeutics Inc., H1 2015 57

Esophageal Cancer-Pipeline by Oncolys BioPharma Inc., H1 2015 58

Esophageal Cancer-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 59

Esophageal Cancer-Pipeline by Patrys Limited, H1 2015 60

Esophageal Cancer-Pipeline by Pfizer Inc., H1 2015 61

Esophageal Cancer-Pipeline by Precision Biologics, Inc., H1 2015 62

Esophageal Cancer-Pipeline by Proteo, Inc., H1 2015 63

Esophageal Cancer-Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2015 64

Esophageal Cancer-Pipeline by Supratek Pharma Inc., H1 2015 65

Esophageal Cancer-Pipeline by Synta Pharmaceuticals Corp., H1 2015 66

Esophageal Cancer-Pipeline by Takara Bio Inc., H1 2015 67

Esophageal Cancer-Pipeline by Transgene Biotek Limited, H1 2015 68

Esophageal Cancer-Pipeline by Zhejiang BetaPharma Co., Ltd., H1 2015 69

Assessment by Monotherapy Products, H1 2015 70

Number of Products by Stage and Target, H1 2015 72

Number of Products by Stage and Mechanism of Action, H1 2015 75

Number of Products by Stage and Route of Administration, H1 2015 78

Number of Products by Stage and Molecule Type, H1 2015 80

Esophageal Cancer Therapeutics-Recent Pipeline Updates, H1 2015 190

Esophageal Cancer-Dormant Projects, H1 2015 257

Esophageal Cancer-Dormant Projects (Contd..1), H1 2015 258

Esophageal Cancer-Dormant Projects (Contd..2), H1 2015 259

Esophageal Cancer-Discontinued Products, H1 2015 260

List of Figures

Number of Products under Development for Esophageal Cancer, H1 2015 14

Number of Products under Development for Esophageal Cancer-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 16

Number of Products under Investigation by Universities/Institutes, H1 2015 21

Comparative Analysis by Late Stage Development, H1 2015 22

Comparative Analysis by Clinical Stage Development, H1 2015 23

Comparative Analysis by Early Stage Products, H1 2015 24

Assessment by Monotherapy Products, H1 2015 70

Number of Products by Top 10 Targets, H1 2015 71

Number of Products by Stage and Top 10 Targets, H1 2015 71

Number of Products by Top 10 Mechanism of Actions, H1 2015 74

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 74

Number of Products by Top 10 Routes of Administration, H1 2015 77

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 77

Number of Products by Top 10 Molecule Types, H1 2015 79

Number of Products by Stage and Top 10 Molecule Types, H1 2015 79

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advantagene, Inc.

Advaxis, Inc.

Amgen Inc.

ArQule, Inc.

Aslan Pharmaceuticals Pte. Ltd.

AstraZeneca PLC

AVEO Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

Cellectar Biosciences, Inc.

Cerulean Pharma, Inc.

Daiichi Sankyo Company, Limited

Genmab A/S

GlaxoSmithKline plc

Glycotope GmbH

Hutchison MediPharma Limited

ImmunoFrontier, Inc.

ImmunoGen, Inc.

Immunomedics, Inc.

Karyopharm Therapeutics, Inc.

Mebiopharm Co., Ltd.

Meiji Seika Pharma Co., Ltd.

Merrimack Pharmaceuticals, Inc.

Novartis AG

Omeros Corporation

Omnitura Therapeutics Inc.

Oncolys BioPharma Inc.

Ono Pharmaceutical Co., Ltd.

Patrys Limited

Pfizer Inc.

Precision Biologics, Inc.

Proteo, Inc.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Supratek Pharma Inc.

Synta Pharmaceuticals Corp.

Takara Bio Inc.

Transgene Biotek Limited

Zhejiang BetaPharma Co., Ltd.

Esophageal Cancer Therapeutic Products under Development, Key Players in Esophageal Cancer Therapeutics, Esophageal Cancer Pipeline Overview, Esophageal Cancer Pipeline, Esophageal Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com